Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Table 3

Prevalence depending on trial subset (RAKET or Satellite).

		RAKET			Satellite
	EGFRmut	EGFR FISHpos	KRASmut	EGFRmut	EGFR FISHpos
𝑛 =	2*	2**	11	3^†	10^††	8
Inconclusive	2	5	3		3
Median age	69, 71	69, 75	60 (55–73)	47, 54, 62	62 (43–68)	62 (60–67)
Gender F/M	F, F	F, M	55/45%	F, M, M	70/30%	62/38%
PS 0/1	1, 1	1, 1	45/55%	1, 0, 0	60/40%	50/50%
Stage IIIA/IIIB	IIIB, IIIB	IIIB, IIIB	18/82%	IIIA, 2IIIB	20/80%	25/75%
Weight loss > 5%	0	0, 1	27%	0, 0, 1	40%	37%
Histology:
Adenocarcinoma	100%	100%	64%	0%	30%	75%
SCC	0%	0%	18%	67%	50%	0%
NSCLC NUS	0%	0%	18%	33%	20%	25%

* del 19 and L858R (exon 21).
**one overlapping with EGFRmut L858R.
^†G719X (exon 18).
^††two overlapping with KRASmut and one with G719X.